Most of outbreaks, which occurred in Iran from 1977 to 2005, were caused by Ogawa serotype. In recent years, a change has been made in the number of the dominant types of outbreaks in Iran and there has been a shift between Ogawa and Inaba, as the main types of outbreaks in the country (
4). Based on the main results of this study, the highest level of susceptibility was observed in the case of ciprofloxacin (99.6%) and then azithromycin (95%). Nevertheless, it is noteworthy that the levels of resistance to tetracycline (15.1%) and doxycycline (4.2%), which are mentioned as the main drugs, in most of sources, are raised (
11). Hence, the large number of tetracycline resistant cases (14.7%) is remarkable. Various studies in Iran and elsewhere have reported resistance of
V. cholerae to chloramphenicol, erythromycin, kanamycin, tetracycline and sulfamethoxazole/trimethoprim (
12). There was a significant relationship between the antibiotic resistance to tetracycline and doxycycline (P = 0.000), i.e. if a person is resistant to one of these two antibiotics, there is a chance of more than 90% for him/her to be resistant to the other drug, as well.
Comparing the results of this study, with other studies, the following results have been achieved. The Barati and colleagues study shows that the resistance to co-trimoxazole has had an increase and there has not been a notable change in ciprofloxacin susceptibility (
6). In the study of Abera, the resistance to co-trimoxazole was 100%. A high level of resistance to chloramphenicol (94%) and ampicillin (89%) was observed. In this study, all cases were susceptible to doxycycline. The antibiotic susceptibility to ciprofloxacin and erythromycin in that study is almost similar to the results of our study; however, the resistance to ampicillin is greater while for tetracycline is lower (
13). Data generated in the present study revealed that tetracycline, one of the main antimicrobial agents used for cholera treatment, was the most effective antibiotic. Our previous study, during the 2005 outbreak, also showed that all isolated stains of
V. cholerae were susceptible to tetracycline. In Rahbar et al. study, all strains of
V. cholerae that were susceptible to tetracycline, were also susceptible to doxycycline. Doxycycline is used as the first line drug for the treatment of cholera in Iran (
5).
In Seas et al. study, data from these well-conducted trials show clearly that the quinolones are equally effective, as the standard therapy (multiple dose tetracycline regimen or single dose doxycycline regimen), in all clinical parameters (i.e., duration, total volume of stools). However, earlier eradication of bacterium from the stool was attained (
14). In Talkington et al. study, all cases were susceptible to doxycycline and azithromycin. The susceptibility to azithromycin was similar to our study; however, in our study, susceptibility to doxycycline was lower than the result of Talkington study (
15). In Pal et al. study, all the strains were similarly susceptible to ampicillin, chloramphenicol, gentamicin, ciprofloxacin and tetracycline. Ogawa biotype was resistant to furazolidone, nalidixic acid and neomycin. However, the results of the study of Pal et al. are considerably different from the results of our study, in terms of susceptibility to ampicillin and tetracycline and, considering the susceptibility to ciprofloxacin and resistance to co-trimoxazole, they were similar (
16). In Rahbar et al. study, the researchers studied the
V. cholerae epidemic, which occurred in 2005, and showed that all isolated strains were resistant to co-trimoxazole, nalidixic acid and furazolidone. On the contrary, all strains were sensitive to tetracycline, doxycycline, ciprofloxacin, erythromycin and ampicillin (
11).
The results of our study show that the resistance to the doxycycline and tetracycline, which are mentioned by multiple authors as the most common antibiotic drugs for treating cholera, is increasing. However, the drug resistance to ciprofloxacin is very low. The results of this study can be used as an evidence to formulate new guidelines for the treatment of cholera.